Nexsen Targets Mid-2027 FDA Filing As Kidney Test Program Expands
NXN: $0.165 +3.13% · MC: $32M
Nexsen says its RenalSure kidney test is progressing towards a targeted US FDA submission in mid-2027, subject to development and clinical validation. It has also begun a feasibility study with GENSPEED on a complementary cartridge-based test, intended to broaden its offering for hospital monitoring; the company cites a global acute kidney injury diagnostics market forecast to grow from about US$1 billion to about US$2 billion by 2033.

Comments